Endoxifen for breast cancer: Multiple-dose, dose-escalation study characterizing pharmacokinetics and safety in metastatic breast cancer patients.

被引：0
|
作者：
Ahmad, Ateeq
Sheikh, S.
Nagarkar, R.
Singh, J. K.
Krishnan, S.
Shrivastav, S.
Shetty, P.
Kale, P.
Rane, R. C.
Ahmad, I.
机构：
[1] Jina Pharmaceut Inc, Libertyville, IL USA
[2] Curie Manavata Canc Ctr, Nasik, India
[3] Mahavir Canc Sansthan, Patna, Bihar, India
[4] Dr Rai Mem Med Ctr, Madras, Tamil Nadu, India
[5] Lions Canc Detect & Treatment Ctr, Surat, India
[6] Lambda Therapeut Res Ltd, Ahmadabad, Gujarat, India
[7] Intas Pharmaceut Ltd, Ahmadabad, Gujarat, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3089
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
    Cobleigh, MA
    Langmuir, VK
    Sledge, GW
    Miller, KD
    Haney, L
    Novotny, WF
    Reimann, JD
    Vassel, A
    SEMINARS IN ONCOLOGY, 2003, 30 (05) : 117 - 124
  • [22] A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer
    Erica L. Mayer
    M. E. Scheulen
    J. Beckman
    H. Richly
    A. Duarte
    M. M. Cotreau
    A. L. Strahs
    S. Agarwal
    L. Steelman
    E. P. Winer
    M. N. Dickler
    Breast Cancer Research and Treatment, 2013, 140 : 331 - 339
  • [23] A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer
    Mayer, Erica L.
    Scheulen, M. E.
    Beckman, J.
    Richly, H.
    Duarte, A.
    Cotreau, M. M.
    Strahs, A. L.
    Agarwal, S.
    Steelman, L.
    Winer, E. P.
    Dickler, M. N.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 140 (02) : 331 - 339
  • [24] Dose-escalation study to assess the safety, pharmacokinetics and dose-proportionality of RAD
    Kovarik, JM
    Rordorf, C
    Hartmann, S
    Lecaillon, JB
    Greig, G
    Halabi, A
    TRANSPLANTATION, 1999, 67 (07) : S158 - S158
  • [25] Dose-escalation of REgorafenib for patients with previously treated metastatic colorectal cancer - DEREGULATE study
    Nishitai, Ryuta
    Manaka, Dai
    Amaike, Hisashi
    Nozaki, Akira
    Kanai, Masashi
    Yamaguchi, Daisuke
    Yazawa, Takeshi
    Kawashima, Kazuhiko
    Ikeda, Fusao
    ANNALS OF ONCOLOGY, 2015, 26 : 129 - 130
  • [26] Multiple-dose pharmacokinetics and safety of CC-5013 in 15 multiple myeloma patients.
    Wu, A
    Scheffler, MR
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 141S - 141S
  • [27] Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study)
    Shun Ishiyama
    Takeshi Yamada
    Masato Nakamura
    Masanobu Enomoto
    Kiichi Sugimoto
    Hajime Yokomizo
    Chihiro Kosugi
    Ryo Ohta
    Kei Ishimaru
    Hiromichi Sonoda
    Keiichiro Ishibashi
    Hidekazu Kuramochi
    Yoichiro Yoshida
    Daisuke Ichikawa
    Keiji Hirata
    Hiroshi Yoshida
    Yojiro Hashiguchi
    Hideyuki Ishida
    Keiji Koda
    Kenji Katsumata
    Kazuhiro Sakamoto
    International Journal of Clinical Oncology, 2022, 27 : 1300 - 1308
  • [28] Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study)
    Ishiyama, Shun
    Yamada, Takeshi
    Nakamura, Masato
    Enomoto, Masanobu
    Sugimoto, Kiichi
    Yokomizo, Hajime
    Kosugi, Chihiro
    Ohta, Ryo
    Ishimaru, Kei
    Sonoda, Hiromichi
    Ishibashi, Keiichiro
    Kuramochi, Hidekazu
    Yoshida, Yoichiro
    Ichikawa, Daisuke
    Hirata, Keiji
    Yoshida, Hiroshi
    Hashiguchi, Yojiro
    Ishida, Hideyuki
    Koda, Keiji
    Katsumata, Kenji
    Sakamoto, Kazuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (08) : 1300 - 1308
  • [29] Pharmacogenomics-pharmacokinetics study of selective estrogen receptor modulators with intra-patient dose-escalation for Japanese breast cancer patients
    Ohno, S.
    Ishiguro, H.
    Yamamoto, Y.
    Takao, S.
    Sato, N.
    Fujisawa, T.
    Kadoya, T.
    Kuroi, K.
    Bando, H.
    Teramura, Y.
    Iwata, H.
    Tanaka, S.
    Toi, M.
    CANCER RESEARCH, 2016, 76
  • [30] First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy
    Noa Avisar
    Liat Adar
    Jason Bock
    Udo Müller
    David Shen
    Steve Barash
    Laurie Pukac
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 929 - 939
12345